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Reocclusion: The Flip Side of Coronary Thrombolysis
FREEK W. A. VERHEUGT, MD, FACQ ALBERT MEIJER, MD,* WIM K. LAGRAND, MD,t 
MACHIEL J. v a n  EENIGE, MSEEt
Nijmegan, Maastricht and Amsterdam, The Netherlands
Since the introduction of thrombolytic therapy for acute 
myocardial infarction, the incidence of coronary artery reocclu- 
sion has been intensively studied. Also, the prediction and diag­
nosis of reocclusion by angiographic and clinical variables, as well 
its invasive and pharmacologic prevention, have gained much 
attention.
By angiographic definition, reocclusion requires three angio­
graphic observations: one with an occluded artery, one with a 
reperfused artery and a third for the assessment of subsequent 
occlusion (true reocclusion). Since the introduction of early 
intravenous reperfusion therapy, most studies use only two angio­
grams: one with a patent and one with a nonpatent infarct-related 
artery. A search for all published reocclusion studies revealed 61 
studies (6,061 patients) with at least two angiograms. The median 
time interval between the first angiogram after thrombolysis and 
the second was 16 days (range 0.1 to 365). Reocclusion was 
observed in 666 (11%) of 6,061 cases. Interestingly, the 28 true 
reocclusion studies showed an incidence of reocclusion of 16 ± 
10% (mean ± SD), and the 33 studies with only two angiograms
10 ± 8% (p = 0.04), suggesting that proven initial occlusion of the 
infarct-related artery is a risk factor for reocclusion after success­
ful thrombolysis. The other predictors for reocclusion are proba­
bly severity of residual stenosis of the infarct-related artery after 
thrombolysis and perhaps the flow state after lysis. Reocclusion is 
most frequently seen in the early weeks after thrombolysis. The 
clinical course in patients with reocclusion is more complicated 
than in those without this complication. Left ventricular contrac­
tile recovery after thrombolysis is hampered by reocclusion.
Routine invasive strategies have not been proven effective 
against reocclusion. In the prevention of reocclusion, both anti­
platelet and antithrombin strategies have been tested, including 
hirudin and hirulog, but the safety of these agents in thrombolysis 
is still questionable.
Thus, reocclusion after thrombolysis is an early phenomenon 
and is more frequent after proven initial occlusion of the infarct- 
related arteiy. Reocclusion can be predicted by angiography after 
thrombolysis. Because reocclusion is detrimental, strategies to 
prevent it should be developed and carried out after thrombolytic 
therapy for acute myocardial infarction as soon as they are 
deemed safe.
(JAm Coll Cardiol 1996;27:766-73)
Besides bleeding, a major drawback of thrombolytic therapy 
for acute myocardial infarction is the increased incidence of 
recurrent ischemia, probably a result of coronary artery reoc- 
clusion (1). This review deals with the pathologic, clinical, 
angiographic, therapeutic and prognostic aspects of coronary 
reocclusion after thrombolytic therapy for acute myocardial 
infarction, as well as the strategies to prevent it.
Definition of Reocclusion
The angiographic definition of coronary reocclusion is 
literally that it occurs after 1) angiographically proven initial 
occlusion of the infarct-related vessel, 2) angiographically 
proven subsequent successful coronary recanalization, and 3)
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angiographically proven subsequent occlusion of the infarct- 
related vessel. Although angiography is still the reference 
standard for defining reocclusion, its snapshot characteristic 
makes it almost useless in clinical practice. Clinical signs of 
reperfusion and reocclusion are better guidelines, but they lack 
sensitivity and specificity. Interestingly, in patients with chest 
pain and ST segment elevation, angiographic “spontaneous” 
reperfusion is seen in 18% to 20% of cases (2,3). Since the 
introduction of early intravenous thrombolysis, angiography is 
mostly performed after initial treatment. Loss of coronary 
patency between two angiographic observations is usually 
called reocclusion. Because of these reasons, single angio­
graphic observations showing an occluded infarct-related ar­
tery after thrombolysis can hardly represent reocclusion, al­
though sometimes clinicians erroneously call lack of patency 
reocclusion.
The angiographic classification of patency is important to 
note. Two grading systems have been used: the European 
Cooperative Study Group (4) and the Thrombolysis in Myo­
cardial Infarction (TIMI) flow grade classification (2). Cur­
rently the TIMI flow grade classification is most widely used, 
and recently it was shown that insufficient flow, like TIMI flow 
grade 2, is clinically almost identical to TIMI flow grade 0 to 1
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(5,6). With this in mind, reocclusion in the most clinically used 
way means the evolution of TIMI flow grade 3 to absent or low 
clinical flow states (TIMI flow grade 0 to 2). The large 
combined outcome and angiographic Global Utilization of 
Streptokinase and t-PA for Occluded Coronary Arteries 
(GUSTO) study yielded insight into the clinical consequences 
of the several flow states in reperfusion therapy for acute 
myocardial infarction (6)*
Pathogenesis of Reocclusion
The pathologic and angiographic observations with throm­
bolytic therapy have firmly established the role of thrombosis 
in the pathogenesis of acute myocardial infarction. Plaque 
rupture probably causes activation of blood platelets and the 
coagulation cascade, resulting in total thrombotic occlusion of 
a coronary artery. Depending on the area at risk, collateral 
blood flow and the duration of occlusion, the resulting infarct 
will be large or small with little sequelae or with deleterious 
consequences to the patient. Reperfusion therapy is aimed at 
early restoration of blood flow by dissolving or removing 
thrombotic material at the site of the coronary lesion. Because 
the nidus of coronary thrombus usually is not removed, 
rethrombosis can easily occur. Because thrombosis and throm­
bolysis probably represent a subtle balance, reestablishment of 
the thrombotic state may lead to coronary rethrombosis. 
Remarkably, plasminogen activation with exogenous com­
pounds has the paradoxic effect of activating both platelets and 
thrombin in the acute phase (7-10). Also, incomplete lysis of 
thrombus (11) and plaque swelling after thrombolysis (12) may 
be stimuli for rethrombosis.
The natural history of residual stenosis after thrombolysis 
shows decremental stenosis severity in the majority of patients, 
suggesting ongoing thrombus resolution and plaque repair 
(13). Platelets cannot only be activated by reexposure to the 
damaged vessel, but also by high shear rates (14). After 
thrombolysis a high grade residual stenosis might activate 
platelets by this mechanism. Experimental studies have shown 
that fibrin-rich thrombus may be replaced by platelet-rich 
thrombus that may be highly resistant to lysis (7). However, 
other processes like inflammation and tissue proliferation 
caused by growth factors cannot be excluded, although they 
have not been studied in the setting of reocclusion.
Reocclusion is probably a time-dependent process. How­
ever, some vessels show total obstruction early after thrombo­
lytic therapy and are patent when studied later. Therefore, it 
seems likely that prothrombotic and antithrombotic processes 
continue long after thrombolytic therapy vessel wall repair is 
finished.
Incidence of Reocciusion
The incidence of reocclusion has been intensively studied 
since the introduction of thrombolytic therapy for acute myo­
cardial infarction. Through EMBASE a search for reocclusion 
studies was done using the key words reocclusion and throm­
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bolytic therapy. Between 1980 and 1994, 60 studies with at least 
one follow-up angiogram after angiographically successful 
thrombolytic therapy have been published. They included 
6,061 patients, of whom 666 (11%) sustained reocclusion of the 
infarct-related artery. The median time between the first 
postthrombolysis angiogram and the follow-up angiogram was 
16 days (range 0.1 to 365). The postthrombolysis angiogram 
showed an “open” infarct-related artery or “successful5’ reper­
fusion and the follow-up angiogram an “occluded5’ artery. 
Studies with three angiograms (one with an occluded artery, 
one with a reperfused artery and a third for the assessment of 
reocclusion) are true reocclusion studies. The 28 true reocclu­
sion studies (1,037 patients) show an incidence of reocclusion 
of 16 ± 10% (mean ± SD). The 33 studies (5,024 patients) 
with only two angiograms (one with an open artery and a 
second for the assessment of reocclusion) report a reocclusion 
incidence of 10 ± 8% (p = 0.04 vs, true reocclusion studies). 
This indicates that angiographically proven initial occlusion of 
the infarct-related artery is a risk factor for reocclusion. Two 
of the studies with three angiograms have specifically analyzed 
the difference in reocclusion after angiographically proven 
initial occlusion and angiographically proven initial patency. 
Serruys et al. (15) showed reocclusion of 2 (6%) of 36 initially 
open vessels compared with 19 (21%) of 91 initially occluded 
vessels (p <  0.05). For TIMI-I (2), these figures were 2 (5%) of 
40 and 19 (21%) of 91 (p <  0.05).
Because of the snapshot characteristic of the angiographic 
approach, other diagnostic criteria (see later) are eagerly 
awaited. In the meantime, reocclusion can only be detected by 
angiography, with its important limitations, such as cost and 
safety. The time window for the diagnosis of reocclusion is very 
important. The first observation of patency is usually per­
formed between 60 and 180 min after initiation of thrombolytic 
therapy. Follow-up angiography can be performed as early as 
24 h after the first angiogram. The Thrombolysis and Angio­
plasty in Myocardial Infarction (TAMI) trial, the largest study 
reporting on in-hospital reocciusion comprised 642 patients, 
demonstrated reocciusion of ~9%  after successful thrombo­
lytic therapy and 17% reocciusion after initially failed throm­
bolytic therapy followed by coronary angioplasty (16). Another 
reported large study of in-hospital reocciusion was GUSTO 
trial, which showed a low reocciusion rate of - 6% (6), 
Reocciusion in the first year after thrombolysis is more fre­
quent. Probably the large time window between which the 
angiograms are obtained (e.g, the first days of thrombolysis 
followed by angiography at 3 months) forms the explanation 
for the high incidence. Reocciusion diagnosed at 3 months 
might be as high as 18% to 32% (17-19). Data on vessel 
patency 1 year after thrombolytic therapy revealed about the 
same incidence (20).
To study reocciusion over time, the incidence of reocciusion 
and the time of the second angiogram are plotted in Figure 1, 
Because reocciusion occurs in a minority of patients treated 
with thrombolysis, only the larger studies were taken into 
account, A cutoff point of 75 patients was chosen. Table 1 
summarizes the 20 studies fulfilling these criteria (2,5,16,18,
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TIME IN MONTHS
Figure 1. Incidence of reocclusion after thrombolysis in the published 
studies with >75 patients. T he x axis represents the time betw een the 
initiation of thrombolytic therapy and the time of follow-up angiogra­
phy.
20-33). Figure 1 clearly shows that reocclusion is most fre­
quent in the first week after thrombolysis and its incidence 
levels off in the ensuing months. The incidence of reocclusion 
after thrombolytic therapy increases with the time window of 
observation, The snapshot approach is probably the cause of 
this phenomenon, In contrast, it is quite possible that vessels 
may reocclude intermittently, which is not diagnosed by the 
follow-up angiogram.
About 25% of patients treated with thrombolytic therapy 
for acute myocardial infarction fail to achieve reperfusion, 
leaving only 75% of successfully treated patients. It is clear 
from the GUSTO trial that early complete vessel patency with 
TIMI flow grade 3 is only observed in -50%  of patients 
undergoing thrombolytic therapy. Approximately 30% of pa­
tients will experience reocclusion in the subsequent months, 
leaving much less than 50% of patients with successful sus­
tained full reperfusion. Thus, only a minority of patients will 
have full sustained benefit from thrombolytic therapy.
A 21% incidence of reocclusion after primary angioplasty 
for acute myocardial infarction was reported recently in the 
Primary Angioplasty Myocardial Infarction (PAMI) trial in­
volving a limited number of patients: 33 of 154 patients had 
TIMI flow grade 0 to 2 six months after successful primary 
angioplasty (34). The incidence of restenosis was reported to 
be -25%  at 3 months (35) and 45% at 6 months (34).
Reocclusion data on thrombolysis in the randomized trials of 
primaiy angioplasty versus thrombolysis are lacking.
Noninvasive Indicators of Reocclusion
b
Clinical variables have been intensely tested in the predic­
tion and diagnosis of coronaiy reperfusion. In the absence of 
angiography, successful reperfusion is as difficult to diagnose as 
subsequent reocclusion. Relief of chest pain, disappearance of 
ST segment elevation and the occurrence of accelerated 
idioventricular rhythm are all indicators, but no proof of 
successful reperfusion. When they are combined, they are 
more indicative of reperfusion, and when none of them are 
present, persistent occlusion is likely. The introduction of 
continuous 12-lead ST segment monitoring has made the 
noninvasive diagnosis of failed reperfusion much more sensi­
tive than the other clinical variables (36).
Recurrence of chest pain and ST segment elevation and 
reinfarction are probably indicators of reocclusion. Also, con­
tinuous 12-lead ST segment monitoring might be a more 
sensitive indicator of reocclusion after coronary thrombolysis 
(37). Other diagnostic tools like thallium-201 or technetium 
sestamibi have not been tested in the diagnosis of reocclusion.
Prediction of Reocclusion
After thrombolysis, smoking and the continuation of smok­
ing have been identified as the only independent predictors of 
reinfarction (38), not of reocclusion, and because reinfarction 
is only a part of the spectrum of reocclusion, no clearcut 
clinical variables can be identified as risk determinants for 
reocclusion.
Angiographic predictors of reocclusion may include flow 
status, stenosis severity and morphology of the culprit lesion. 
Studies specifically aimed at identifying the incidence of reoc- 
clusion, not recurrent ischemia (39), are the TAMI (16), 
TIMI-4 (33), Aspirin Versus Coumadin Trial (APRICOT) 
(40) and GUSTO (41) studies and the study by White et al. 
(20). A  poor flow state (TIMI flow grade 0 or 1) of the 
infarct-related artery at 90 min after thrombolysis initiation 
was a significant predictor of subsequent reocclusion in the 
TAMI trials and the TIMI-4 study. However, this finding could 
not be confirmed in the GUSTO angiographic study (41). In 
the APRICOT study, reocclusion was the primary end point in 
284 patients, and only patients with TIMI flow grade 3 were 
included. All patients with TIMI flow grade 2 or less were 
regarded as showing reocclusion on the second angiogram. It 
was clearly shown that stenosis severity is an independent risk 
factor (odds ratio 2.3) for the occurrence of reocclusion. 
Interestingly, a smooth morphology of the culprit lesion is also 
associated with reocelusion. Also, in the trial by White et al. 
(20) and the TIMI-4 study (33), residual stenosis severity 
proved to be a predictor of reocclusion in the year after 
successful thrombolysis.
As stated previously, angiographically proven initial occlu­
sion of the infarct-related artery seems to be a risk factor for 
subsequent reocclusion. Thus, the risk of reocclusion can 
probably be predicted by early angiographic observation both 
before and after thrombolytic therapy.
Consequences of Reocclusion
The presence of both an initially open artery and salvaged 
myocardium may determine the clinical manifestations of 
reocclusion. Reocclusion may be associated with recurrent 
angina, reinfarction, pump failure and death. It may also occur 
without symptoms. Symptomless reocclusion may be associ­
ated with the presence of collateral channels protecting the 
salvaged myocardium against renewed damage at the time of 
reocclusion. In contrast, symptomless reocclusion may also 
indicate a lack of initially salvaged myocardium. This question 
has not yet been answered, and no conclusive studies evaluat­
ing the presence of myocardial viability and consequences of
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Table 1, Reocclusion Rates After Successful Thrombolysis (summary o f trials with at least 75 patients)
First Author or Study 
Name (ref no.) No. of Pts* Angiogram
Angiographic 
Time Window
Thrombolytic
Agent
Average Reocclusion
(%)
Serruys (15) 91 1st Acute, serial IC (+IV ) SK 21
2nd 2-8 wk
Timmis (21) 95 1st Acute, serial IC SK 14
2nd 10-24 d
TIMI-I (2) 91 1st Acute, serial SK, tPA 19
2nd 5-25 d
TAMI-1 (22) 197 1st 90 min tPA 12
2nd 7-10 d
Uebis-1 (23) 106 1st Acute, serial IC SK 6
2nd 3 d
Uebis-2 (23) 76 1st Acute, serial IC SK 25
2nd 6 mo
Anderson et al. (24) 77 1st 90 min IC SK, APSAC 5
2nd <24 h
PRIMI (30) 213 1st 45-75 min pro-UK 3
2nd 24-36 h
Ohman (16) 419 1st 90 min IV UK, tPA, 9
2nd 7 d IV UK+tPA
TAMI 1-5 (26) 607 1st 90 min IV UK, tPA, 11
2nd 7—10 d IV UK+tPA
TEAM-2 (25) 190 1st 90-240 min SK, APSAC 2
2nd I d
ARMS (28) 102 1st 90 min APSAC 4
2nd 24 h
TAMI-7 (27) 157 1st 90 min IV UK, tPA 7
2nd 5-10 d
TAPS-1 (29) 339 1st 90 min APSAC, tPA 6
2nd 24-48 h
TAPS-2 (29) 339 1st 90 min APSAC, tPA 11
2nd 14-21 d
HART (31) 98 1st 7-24 h tPA 9
2nd 7 d
APRICOT (18) 248 1st <48 h SK, APSAC 29
2nd 3 mo
GUSTO (6) 586 1st 90 min SK, tPA, 6
2nd 5-7 d SK+tPA
TIMI-5 (32) 183 1st 90 min tPA 4
2nd 16-36 h
White (20) 154 1st 4 wk SK, tPA 25
2nd ly r
TIMM (33) 278 1st 90 min APSAC, tPA 5
2nd 18-36 h
*With angiographically successful thrombolysis and with one or more follow-up angiograms. APRICOT = 
Antithrombotics in the Prevention of Reocclusion in Coronary Thrombolysis; APSAC ~ anisoylated plasminogen 
streptokinase activator complex; ARMS = APSAC Reocclusion Multicenter Study; d = day; GUSTO = Global 
Utilization of Streptokinase and tPA for Occluded Coronary Arteries; HART = Heparin-Aspirin Reperfusion Trial; IC 
= intracoronary; IV = intravenous; PRIMI = Pro-Urokinase in Myocardial Infarction; pro-UK = pro-urokinase; Pts = 
patients; ref = reference; SK = streptokinase; TAMI = Thrombolysis and Angioplasty in Myocardial Infarction; TAPS 
= t-PA APSAC Patency Study; TEAM = Trial of Eminase Versus Alteplase in Myocardial Infarction; TIMI = 
Thrombolysis in Myocardial Infarction; tPA = tissue-type plasminogen activator; UK = urokinase.
collateral channels after reocclusion are available. Some large 
studies showed that reocclusion precludes left ventricular 
contractile recovery (16,20,42), especially in the infarcted 
region of the left ventricle. This occurs also in the absence of 
clinical reinfarction (41). Reocclusion in the anterior region of 
the left ventricle has the worst consequences for global left
ventricular function (42). Apparently, reocclusion is deleteri­
ous for long-term left ventricular function and indirectly 
indicates that myocardial viability exists after successful throm­
bolysis.
Recurrent angina is a poor indicator of reocclusion. Angina 
is a symptom notoriously difficult to interpret. Reinfarction
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Table 2. Random ized, Controlled Trials W ith Two Angiograms for Prevention o f Reocclusion W ith H eparin A fter Successful 
Coronary Thrombolysis
Study (ref no.)
No. of 
Pts 1st Angiogram 2nd Angiogram
Reocclusion With Heparin 
[no. (%) of pts]
Reocclusion With Control 
[no. (%) of pts]
P
Value
APRICOT (18) 155 23 h (median) 3 mo 24/81 (30%)* 24/74 (32%)t NS
HART (31) 98 18 h (mean) 7d 7/60 (12%)f 2/38 (5%)t NS
^Patients were not receiving aspirin; warfarin was started with heparin; heparin was discontinued when thromboplastin time was therapeutic. fPatients were not 
receiving aspirin. ^Patients were receiving aspirin, 80 mg/day. Abbreviations as in Table 1.
early after thrombolytic therapy is probably due to reocclusion 
because its incidence is twice as high as that for with control 
treatment (3,43,44), Depending on the definition, the reinfarc­
tion rate can be as high as 13% (45). To our knowledge, a hard 
correlation between reocclusion and reinfarction has never 
been made. This correlation is scarcely possible because in the 
search for reocclusion, one is forced to use the snapshot 
approach. It is likely that reinfarction is the result of reocclu­
sion. Because reocclusion impedes recovery of left ventricular 
function, it is understandable that mortality is higher with than 
without reocclusion (16). In the thrombolysis-only arms of the 
TAMI studies 5 (12.8%) of 39 patients with reocclusion died 
versus 15 (4%) of 380 patients without reocclusion (p <  0.02).
Prevention of Reocclusion
Strategies to prevent reocclusion may be invasive or nonin- 
vasive. Invasive strategies consisting of early angiography 
followed by angioplasty have been tested extensively in the 
prevention of reocclusion after successful coronary thrombol­
ysis (46). The largest study, carried out in the United States, 
prospectively analyzed a routine invasive versus a routine 
conservative strategy after thrombolysis with tissue-type plas­
minogen activator (t-PA) (47). It was clearly shown that a 
routine invasive strategy does not prevent recurrent ischemia, 
reinfarction or death, nor does it preserve residual left ventric­
ular function after thrombolytic therapy for acute myocardial 
infarction. Also, the long-term efficacy of this strategy has not 
been proven. Apparently, manipulation by angioplasty of a 
postthrombolytic coronary lesion, which contains or has con­
tained thrombotic material, exposes the patient to untoward 
effects of angioplasty, like total occlusion or vessel dissection. 
Another invasive strategy to prevent reocclusion is aortic 
balloon counterpulsation immediately after thrombolysis. In 
one large trial (48), this proved to be effective, but these results 
should be confirmed in another study.
Noninvasive methods to prevent reocclusion have also been
evaluated and seem to be partially effective. However, in 
analyzing the data, one should clearly discriminate between 
early coronary patency and proven coronary reocclusion. For 
the diagnosis of early patency, one needs only one angiogram. 
For the diagnosis of reocclusion, one needs at least two 
angiograms: one with a patent and one with a subsequently 
occluded coronary lesion.
Heparin has been extensively tested after thrombolysis, 
especially with t-PA. Coronary patency evaluated in the first 
hours or days after thrombolytic therapy with t-PA is better 
with than that without intravenous heparin (31,49,50). These 
data do not necessarily prove that heparin, when used in 
conjunction with t-PA, actually prevents reocclusion. Random­
ized, controlled studies on the effect of intravenous heparin in 
the prevention of reocclusion after angiographically proven 
successful coronary thrombolysis are scarce and have a nega­
tive outcome (Table 2). Intravenous heparin followed by 
warfarin sodium (Coumadin) does not prevent long-term 
reocclusion either (18). Heparin infusion after t-PA for acute 
myocardial infarction is probably necessary during a short time 
and can be discontinued 24 h after thrombolytic therapy (51). 
Heparin therapy is notoriously difficult to monitor, which 
might be the reason for its apparent ineffectiveness in prevent­
ing reocclusion. Partial activated thromboplastin time is the 
usual measure for heparin anticoagulation. There is a correla­
tion between adequacy of heparinization and coronary patency 
(49), but its relation to reocclusion after successful thrombol­
ysis has not been systematically studied. Close monitoring of 
heparin therapy after thrombolysis is mandatory not only for 
patency and possibly reocclusion but also for the prevention of 
bleeding. Partial activated thromboplastin time values >90 s 
after thrombolysis are correlated with an unacceptable risk of 
cerebral bleeding (52,53). Hirudin and hirulog, highly specific 
antithrombin agents, seem to be more effective than heparin in 
the prevention of reocclusion after t-PA (32) or streptokinase 
(54) (Table 3). However, patient numbers in these trials are 
small, and although more simple than with heparin, hirudin
Table 3. Randomized, H eparin-Controlled Trial W ith Two Angiogram s fo r P revention o f Reocclusion W ith Hirudin or Hirulog After 
Successful Coronary Thrombolysis
1st Author or Study No. of Reocclusion With Agent Reocclusion With Heparin P
Name (ref no.) Pts Agent 1st Angiogram 2nd Angiogram [no. (%) of pts] t [no. (%) of pts] Value
TIMI-5 (32) 165 Hirudin 90 min 16-36 h 1/105 (1%) 4/60 (7%) 0.05
Lidon (54) 45 Hirulog 90 min 5 d 0/30 (0%) 1/15 (7%) NS
Abbreviations as in Table L
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Table 4. Randomized, Controlled Trials With Two A ngiogram s for Prevention o f Reocclusion W ith Aspirin A fter Successful 
Coronary Thrombolysis
1st Author or Study Name
(ref no.)
No. of 
Pts 1st Angiogram 2nd Angiogram
Reocclusion With Aspirin 
[no. (%) of pts]
Reocclusion With Control 
[no. (%) of pts]
P
Value
APRICOT (18) 167 23 h (median) 3 mo 23/93 (25%) 24/74 (32%) NS
White (20) 154 4 wk 1 yr 18/79 (23%) 20/75 (27%) NS
HART (31) 98 18 h (mean) 7 d 2/38 (5%) 7/60 (12%)f NS
*Combined with dipyridamole, 200 rag twice a day. fPatients were receiving intravenous heparin with a partial activated thromboplastin time between 1.5 and 2.0 s. 
Abbreviations as in Table 1.
also needs close monitoring, because it is associated with more 
cerebral bleedings than heparin (52,53,55),
The role of antiplatelet therapy after thrombolytic therapy 
in the prevention of reinfarction has been firmly established 
(43). However, the mechanism by which this benefit is achieved 
is not clear (56). Many believe that antiplatelet therapy
treated. If it occurs early, rethrombolysis is an option, although 
revascularization seems to be a more definite solution.
The optimal time for angiography after thrombolytic ther­
apy for acute myocardial infarction is probably several days 
before hospital discharge. The patency of the infarct-related 
vessel can be used for risk stratification for either reocclusion
prevents reocclusion after thrombolysis, but this has never or further left ventricular functional recovery. Culprit lesion
been proved. Patency after thrombolysis is better with aspirin severity tends to diminish over time (13) and a not severely
than without it (57), but this does not prove aspirin prevents stenosed infarct-related artery will not reocclude easily (40).
reocclusion. Placebo-controlled studies with aspirin in success- When the infarct-related vessel is open but severely stenosed,
fully thrombolyzed patients with follow-up angiograms are revascularization seems to be indicated, because these vessels
scarce. They show that aspirin only tends to prevent reocclu- tend to reocclude (13,20). If the infarct-related vessel is
sion (18,20,57) (Table 4).
Because the reocclusion trials with heparin and aspirin are 
few in number and small in size, large-scale angiographic
occluded, angioplasty can be carried out to allow left ventric­
ular contractile recovery (58). Patients with minimal infarction 
in relation to estimated risk area and those in whom viable
studies are necessary to identify the role of these agents in the myocardium can be shown to be present with nuclear tech-
prevention of reocclusion. However, placebo-controlled stud- niques (59,60) or dobutamine stress echocardiography (61,62)
ies cannot be carried out any more because the place of these might benefit from this procedure. Angioplasty of the infarct-
drugs in the standard thrombolytic strategies for optimal related artery a few days before hospital discharge is feasible
patency and reduction of reinfarction has been firmly estab­
lished.
because the vascular occlusion must be very recent, and is 
probably also safer than angioplasty early after thrombolysis.
Primary angioplasty without the use of thrombolysis might However, a strategy of predischarge angiography with sub- 
eliminate factors in the culprit lesion leading to reocclusion. sequent revascularisation of severely stenosed or occluded 
However, as stated before, the reocclusion rate after this infarct-related arteries supplying viable myocardium has not 
therapy has been reported in only a limited number of patients 
and does not seem to differ from reocclusion after thrombol-
been tested yet in a large randomized trial For this purpose at 
least 300 patients should be randomized to show, with a power
ysis, although more data from randomized trials are necessary. of 80%, a statistically significant 50% reduction of an expected 
Currently several antiplatelet and antithrombin strategies 25% reocclusion of very tightly stenosed or occluded infarct
after thrombolytic therapy are being clinically tested.
Treatment of Reocclusion
As stated previously, coronary occlusion is detrimental to 
left ventricular contractile recovery, even in the absence of 
clinical reinfarction. Many believe that once reocclusion is 
diagnosed, thrombolytic therapy for acute myocardial infarc­
tion has failed, Interestingly, -50%  of reocclusions are not
vessels that are dilated at hospital discharge. As yet, invasive 
strategies in the prevention and treatment of reocclusion after 
thrombolysis cannot be recommended for routine clinical 
practice.
Conclusions
Reocclusion after thrombolytic therapy for acute myocar­
dial infarction remains a major problem in everyday cardiol-
accompanied by clinical recurrent infarction or recurrent isch- ogy. It is probably thrombotic in origin and its incidence varies
emia (16) and thus are silent. Reperfusion therapy with strongly at the time of diagnosis: from 5% to 30%. The highest
angioplasty even weeks after myocardial infarction seems to he incidence is seen after proven initial occlusion of the infarct- 
beneficial in selected patients in terms of left ventricular 
functional recovery (58). Therefore, it seems that myocardial
viability exists even after the occurrence of reocclusion. If the first year. Reocclusion interferes with left ventricular
silent reocclusion leaves myocardial tissue viable, it could be contractile recovery and also seems to be associated with high
related arteiy. The incidence is —5% to 10% during the 
hospital stay for the index infarction and levels off to ~30% in
morbidity and mortality. It might be predicted by early angiog­
raphy, but so far invasive strategies have failed to prevent it. 
Whether reocclusion can be prevented by the use of antithrom­
botic agents is still unclear. Both heparin and aspirin are 
associated with better patency, but randomized, controlled 
trials with these agents in the prevention of angiographically 
proven reocclusion are small and inconclusive. More anti­
thrombotic and antiplatelet drugs need to be tested in the 
prevention of reocclusion.
Because reocclusion is often silent, it is possible that viable 
myocardium remains even after reocclusion. Therefore, inva­
sive treatment of coronary reocclusion may be an option in the 
further improvement of thrombolytic therapy, but this should 
be tested first in a randomized trial. Both the prevention and 
treatment of reocclusion after thrombolytic therapy are main 
fields of future clinical research.
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